KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Operating Expenses (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Operating Expenses data on record, last reported at $409.8 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 21.47% year-over-year to $409.8 million; the TTM value through Dec 2025 reached $1.3 billion, up 11.63%, while the annual FY2025 figure was $1.3 billion, 10.95% up from the prior year.
  • Operating Expenses reached $409.8 million in Q4 2025 per IONS's latest filing, up from $316.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $409.8 million in Q4 2025 and bottomed at $198.7 million in Q2 2021.
  • Average Operating Expenses over 5 years is $273.9 million, with a median of $278.5 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: dropped 29.89% in 2021, then soared 64.04% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $219.4 million in 2021, then soared by 64.04% to $359.9 million in 2022, then fell by 8.14% to $330.6 million in 2023, then increased by 2.05% to $337.4 million in 2024, then increased by 21.47% to $409.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $409.8 million in Q4 2025, $316.9 million in Q3 2025, and $312.2 million in Q2 2025.